Tumor-Draining Lymph Node Reconstruction Promotes B Cell Activation During E0771 Mouse Breast Cancer Growth.
B cell
Lymph node conduits
Tumor-draining lymph node
breast cancer
follicular dendritic cell (FDC)
germinal center (GC)
subcapular sinus macrophage
tumor-associated antigen (TAA)
Journal
Frontiers in pharmacology
ISSN: 1663-9812
Titre abrégé: Front Pharmacol
Pays: Switzerland
ID NLM: 101548923
Informations de publication
Date de publication:
2022
2022
Historique:
received:
30
11
2021
accepted:
03
03
2022
entrez:
14
4
2022
pubmed:
15
4
2022
medline:
15
4
2022
Statut:
epublish
Résumé
Lymph node metastasis is associated with tumor aggressiveness and poor prognosis in patients. Despite its significance in cancer progression, how immune cells in the tumor-draining lymph node (TDLN) participate in cancer immune regulation remains poorly understood. It has been reported that both anti-tumor and exhausted tumor-specific T cells can be induced in the TDLNs; however, B cell activation and maturation in the TDLN has received far less attention. In our studies using C57BL/6 mouse syngeneic E0771 breast cancer or B16F10 melanoma cell lines, tumor-associated antigens were found colocalized with the follicular dendritic cells (FDCs) in the germinal centers (GCs), where antigen-specific B cell maturation occurs. LN conduits and the subcapsular sinus (SCS) macrophages are two major routes of antigen trafficking to FDCs. Tumor growth induced LN conduit expansion in the B cell zone and disrupted the SCS macrophage layer, facilitating both the entry of tumor-associated antigens into the B cell zone and access to FDCs located in the GCs. Regional delivery of clodronate liposome specifically depleted SCS macrophages in the TDLN, increasing GC formation, and promoting tumor growth. Our study suggests that TDLN reconstruction creates a niche that favors B cell activation and maturation during tumor growth.
Identifiants
pubmed: 35418862
doi: 10.3389/fphar.2022.825287
pii: 825287
pmc: PMC8995528
doi:
Types de publication
Journal Article
Langues
eng
Pagination
825287Informations de copyright
Copyright © 2022 Louie, Oo, Leung, Lin, Stephens, Alrashed, Tso and Liao.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Immunity. 2012 Mar 23;36(3):415-26
pubmed: 22386268
Cancer Immunol Immunother. 2009 Feb;58(2):221-34
pubmed: 18568347
Clin Cancer Res. 2018 Dec 15;24(24):6125-6135
pubmed: 30049748
Nature. 2020 Jan;577(7791):549-555
pubmed: 31942075
Nat Immunol. 2009 Jul;10(7):786-93
pubmed: 19503106
Immunity. 2009 Feb 20;30(2):264-76
pubmed: 19185517
Sci Transl Med. 2020 Sep 30;12(563):
pubmed: 32998971
J Immunol. 2010 Nov 1;185(9):4977-82
pubmed: 20962266
Nat Rev Cancer. 2012 Feb 24;12(3):210-9
pubmed: 22362216
Annu Rev Immunol. 2011;29:215-33
pubmed: 21219172
Immunity. 2013 Oct 17;39(4):782-95
pubmed: 24138885
Front Immunol. 2015 Mar 13;6:114
pubmed: 25821451
Science. 2018 Mar 23;359(6382):1408-1411
pubmed: 29567714
Nat Rev Immunol. 2010 Dec;10(12):813-25
pubmed: 21088682
Cancer. 1991 Jun 1;67(11):2880-6
pubmed: 1709062
Nat Rev Immunol. 2020 May;20(5):294-307
pubmed: 31988391
Trends Cancer. 2016 Dec;2(12):747-757
pubmed: 28626801
Blood. 2009 Dec 3;114(24):4989-97
pubmed: 19713459
N Engl J Med. 2010 Aug 19;363(8):711-23
pubmed: 20525992
Cancer Immunol Res. 2015 Dec;3(12):1356-63
pubmed: 26297710
J Innate Immun. 2012;4(5-6):424-36
pubmed: 22488251
Cell Rep. 2021 Apr 13;35(2):108993
pubmed: 33852863
Nature. 2020 Jan;577(7791):556-560
pubmed: 31942077
Cell. 2017 Sep 7;170(6):1120-1133.e17
pubmed: 28803728
Cell. 2017 May 4;169(4):736-749.e18
pubmed: 28475899
Cancer Immunol Immunother. 2009 Oct;58(10):1535-44
pubmed: 19562338
Am J Pathol. 2006 Aug;169(2):708-18
pubmed: 16877368
Clin Cancer Res. 2016 Jun 15;22(12):3005-15
pubmed: 26763251
Science. 2015 Feb 6;347(6222):667-72
pubmed: 25657250
Immunol Res. 2013 Dec;57(1-3):115-24
pubmed: 24293009
Curr Opin Immunol. 2017 Apr;45:43-51
pubmed: 28192720
J Clin Invest. 2015 Sep;125(9):3384-91
pubmed: 26325035
Science. 2018 Mar 23;359(6382):1403-1407
pubmed: 29567713
Cancer Immunol Immunother. 2011 May;60(5):609-19
pubmed: 21253724
Nature. 2020 Jan;577(7791):561-565
pubmed: 31942071
Cell. 2012 Sep 14;150(6):1235-48
pubmed: 22980983
Cancer Sci. 2018 May;109(5):1723-1730
pubmed: 29520898
Nature. 2010 Jun 24;465(7301):1079-83
pubmed: 20577213
Cell. 2021 Dec 9;184(25):6101-6118.e13
pubmed: 34852236
Nat Med. 2019 Feb;25(2):312-322
pubmed: 30643287
Oncol Lett. 2017 May;13(5):3225-3232
pubmed: 28521429
Int J Cancer. 2005 Nov 20;117(4):574-86
pubmed: 15912532
Trends Immunol. 2016 Dec;37(12):844-854
pubmed: 27793570
J Virol. 2015 Jul;89(14):7147-58
pubmed: 25926638
Science. 2016 Apr 8;352(6282):242-6
pubmed: 26989197
Cancer Cell. 2020 Nov 9;38(5):685-700.e8
pubmed: 33007259
J Pathol. 2016 Jun;239(2):231-41
pubmed: 27174787
Cancer Sci. 2013 Sep;104(9):1237-44
pubmed: 23734742